Literature DB >> 10520944

Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease.

O L Lopez1, S R Wisniewski, J T Becker, F Boller, S T DeKosky.   

Abstract

OBJECTIVE: To examine whether the use of psychiatric medication and the presence of abnormal behaviors affects the progression of Alzheimer disease.
DESIGN: Cross-sectional with longitudinal follow-up and the likelihood of arriving at 4 end points: (1) Mini-Mental State Examination score of 9 or lower; (2) Blessed Dementia Rating Scale score of 15 or higher for activities of daily living; (3) nursing home admission; and (4) death, evaluated using a proportional hazard model with 9 variables: psychosis, insomnia, wandering, aggression, psychomotor agitation, depression, and use of antidepressants, antipsychotic agents, or sedatives/hypnotics.
SETTING: Multidisciplinary dementia research clinic. PATIENTS: We examined baseline and follow-up behavioral symptoms and the use of psychiatric medication in 179 mildly to moderately impaired patients with probable Alzheimer disease participating in a longitudinal study of dementia. Patients were observed from 2.4 to 172 months (mean duration +/- SD, 49.5+/-27.4 months).
RESULTS: Nine patients (5%) were taking sedatives/ hypnotics; 16 (9%), antipsychotic agents; and 22 (12%), antidepressants at study entry. Patients taking antipsychotic agents had lower Mini-Mental State Examination scores and higher Blessed Dementia Rating Scale scores for activities of daily living than patients not taking any medication. Using proportional hazard analysis with time-dependent covariates for individual psychiatric symptoms and medications, we found that the development of psychosis was associated with functional decline (time to Blessed Dementia Rating Scale score of > or =15), institutionalization, aggression, and agitation with functional decline after adjusting for age at study entry, education, Mini-Mental State Examination scores, and Blessed Dementia Rating Scale scores. Use of antipsychotic medication was associated with functional decline, and sedatives/hypnotics with death. Neither the presence of psychiatric symptoms nor use of medication was associated with rate of cognitive decline (time to Mini-Mental State Examination score of < or =9).
CONCLUSIONS: These findings indicate that the use of antipsychotic agents and sedatives can affect the natural course of Alzheimer disease. Psychosis, agitation, and aggression are important predictors of outcome, even when the effects of medication to treat them is taken into account.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10520944     DOI: 10.1001/archneur.56.10.1266

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  55 in total

1.  The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease.

Authors:  P B Rosenberg; M M Mielke; D Han; J S Leoutsakos; C G Lyketsos; P V Rabins; P P Zandi; J C S Breitner; M C Norton; K A Welsh-Bohmer; I H Zuckerman; G B Rattinger; R C Green; C Corcoran; J T Tschanz
Journal:  Int J Geriatr Psychiatry       Date:  2012-02-29       Impact factor: 3.485

2.  Genetic variants associated with susceptibility to psychosis in late-onset Alzheimer's disease families.

Authors:  Sandra Barral; Badri N Vardarajan; Dolly Reyes-Dumeyer; Kelley M Faber; Thomas D Bird; Debby Tsuang; David A Bennett; Roger Rosenberg; Bradley F Boeve; Neill R Graff-Radford; Alison M Goate; Martin Farlow; Rafael Lantigua; Martin Z Medrano; Xinbing Wang; M Ilyas Kamboh; Mahmud Muhiedine Barmada; Daniel J Schaid; Tatiana M Foroud; Elise A Weamer; Ruth Ottman; Robert A Sweet; Richard Mayeux
Journal:  Neurobiol Aging       Date:  2015-08-15       Impact factor: 4.673

3.  Antidepressant Use and Cognitive Decline: The Health and Retirement Study.

Authors:  Jane S Saczynski; Allison B Rosen; Ryan J McCammon; Kara Zivin; Susan E Andrade; Kenneth M Langa; Sandeep Vijan; Paul A Pirraglia; Becky A Briesacher
Journal:  Am J Med       Date:  2015-01-30       Impact factor: 4.965

4.  Risk Factors for Progression of Alzheimer Disease in a Canadian Population: The Canadian Outcomes Study in Dementia (COSID).

Authors:  Nathan Herrmann; Tetsuhiro Harimoto; Robert Balshaw; Krista L Lanctôt
Journal:  Can J Psychiatry       Date:  2015-04       Impact factor: 4.356

5.  Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease.

Authors:  Cynthia A Munro; Crystal Flynn Longmire; Lea T Drye; Barbara K Martin; Constantine E Frangakis; Curtis L Meinert; Jacobo E Mintzer; Anton P Porsteinsson; Peter V Rabins; Paul B Rosenberg; Lon S Schneider; Daniel Weintraub; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2012-12       Impact factor: 4.105

6.  TAR DNA-binding protein 43 pathology in Alzheimer's disease with psychosis.

Authors:  Anil Varma V Vatsavayi; Julia Kofler; Mary Ann A Demichele-Sweet; Patrick S Murray; Oscar L Lopez; Robert A Sweet
Journal:  Int Psychogeriatr       Date:  2014-03-04       Impact factor: 3.878

7.  Risk Factors, Neuroanatomical Correlates, and Outcome of Neuropsychiatric Symptoms in Alzheimer's Disease.

Authors:  Stéphane P Poulin; David Bergeron; Bradford C Dickerson
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

8.  Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.

Authors:  Dong-Churl Suh; Stephen Arcona; Simu K Thomas; Christopher Powers; Adrian L Rabinowicz; Hyunchul Shin; Dario Mirski
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  The relationship of excess cognitive impairment in MCI and early Alzheimer's disease to the subsequent emergence of psychosis.

Authors:  Elise A Weamer; James E Emanuel; Daniel Varon; Sachiko Miyahara; Patricia A Wilkosz; Oscar L Lopez; Steven T Dekosky; Robert A Sweet
Journal:  Int Psychogeriatr       Date:  2008-09-25       Impact factor: 3.878

10.  Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.

Authors:  O L Lopez; J T Becker; A S Wahed; J Saxton; R A Sweet; D A Wolk; W Klunk; S T Dekosky
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-02-09       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.